公开(公告)号：US20100311798A1

公开(公告)日：2010-12-09

申请号：US12789484

申请日：2010-05-28

申请人： Guillaume Décoret ,  Guido Galley ,  Katrin Groebke Zbinden ,  Roger Norcross

发明人： Guillaume Décoret ,  Guido Galley ,  Katrin Groebke Zbinden ,  Roger Norcross

IPC分类号： A61K31/421 ,  C07D263/28

CPC分类号： C07D263/28

摘要： The invention relates to compounds of formula wherein R1, R2, R2′, X, Y, andn are as defined in the specification or to a pharmaceutically suitable acid addition salt thereof. The compounds of formula I are active on the TAAR1 receptor and are therefore suitable for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

摘要翻译： 本发明涉及下式的化合物，其中R1，R2，R2'，X，Y和n如说明书中所定义或其药学上合适的酸加成盐。 式I化合物对TAAR1受体具有活性，因此适用于治疗抑郁症，焦虑障碍，双相情感障碍，注意缺陷多动障碍，应激相关疾病，精神病，精神分裂症，神经系统疾病，帕金森病，神经变性疾病 ，阿尔茨海默病，癫痫，偏头痛，药物滥用和代谢紊乱，饮食失调，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍，体温平衡紊乱和失调，睡眠和昼夜节律紊乱以及心血管 疾病